AVEO - AVEO Pharmaceuticals: Finally Ready To Reboot

• It appears as if AVEO Oncology is off to a strong start. The company is expected to report their fourth-quarter and full-year 2021 earnings on March 14th.
• I have stayed cautiously optimistic about AVEO’s performance in anticipation the Street will continue to be skeptical about FOTIVDA’s launch. I believe the prolonged sell-off has improved the risk-reward.
• My plan of remaining patient and waiting for a couple of quarters of earnings and clarity on COVID-19 appears to have saved me some pain.
• AVEO is now trading well below my current “buy” threshold of $4.36 per share. As a result, I am ready to reboot my AVEO position at these valuations.
• I will discuss how I plan to take my AVEO position out of mothball and quickly get her into the green. I am looking to buy under $3.50 per share.

For further details see: